JP2022506829A - エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン - Google Patents

エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン Download PDF

Info

Publication number
JP2022506829A
JP2022506829A JP2021524438A JP2021524438A JP2022506829A JP 2022506829 A JP2022506829 A JP 2022506829A JP 2021524438 A JP2021524438 A JP 2021524438A JP 2021524438 A JP2021524438 A JP 2021524438A JP 2022506829 A JP2022506829 A JP 2022506829A
Authority
JP
Japan
Prior art keywords
cancer
eribulin
inhibitor
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021524438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506829A5 (https=
JPWO2020097625A5 (https=
Inventor
ジェシカ、エイ．ソレンティノ
パトリック、ジョセフ、ロバーツ
ジェイ、コープランド、ストラム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
G1 Therapeutics Inc
Original Assignee
G1 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G1 Therapeutics Inc filed Critical G1 Therapeutics Inc
Publication of JP2022506829A publication Critical patent/JP2022506829A/ja
Publication of JP2022506829A5 publication Critical patent/JP2022506829A5/ja
Publication of JPWO2020097625A5 publication Critical patent/JPWO2020097625A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021524438A 2018-11-09 2019-11-12 エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン Pending JP2022506829A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862758388P 2018-11-09 2018-11-09
US62/758,388 2018-11-09
PCT/US2019/061010 WO2020097625A1 (en) 2018-11-09 2019-11-12 Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations

Publications (3)

Publication Number Publication Date
JP2022506829A true JP2022506829A (ja) 2022-01-17
JP2022506829A5 JP2022506829A5 (https=) 2022-11-21
JPWO2020097625A5 JPWO2020097625A5 (https=) 2022-11-21

Family

ID=70612537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021524438A Pending JP2022506829A (ja) 2018-11-09 2019-11-12 エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン

Country Status (5)

Country Link
US (1) US20210267986A1 (https=)
EP (1) EP3877422A4 (https=)
JP (1) JP2022506829A (https=)
CN (1) CN113271977A (https=)
WO (1) WO2020097625A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL303038B2 (en) 2016-12-05 2024-08-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
EP3565558B1 (en) 2017-01-06 2023-12-06 G1 Therapeutics, Inc. Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer
ES3048084T3 (en) 2020-05-19 2025-12-09 Pharmacosmos Holding As Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
WO2022087018A1 (en) * 2020-10-19 2022-04-28 G1 Therapeutics, Inc. Improved fluorouracil-based multi-agent chemotherapy for treatment of metastatic colorectal cancer
CN114748480B (zh) * 2021-01-08 2023-10-20 轩竹生物科技股份有限公司 一种预防和/或治疗癌症的药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501213A (ja) * 2012-12-04 2016-01-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がんの処置におけるエリブリンの使用
WO2018016563A1 (en) * 2016-07-20 2018-01-25 Eisai R&D Management Co., Ltd. Use of eribulin and histone deacetylase inhibitors in the treatment of cancer
WO2018106729A1 (en) * 2016-12-05 2018-06-14 G1 Therapeutics, Inc. Preservation of immune response during chemotherapy regimens

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102051881B1 (ko) * 2010-10-25 2019-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
DK2968290T3 (da) * 2013-03-15 2019-11-25 G1 Therapeutics Inc Transient beskyttelse af normale celler under kemoterapi
AU2015225436A1 (en) * 2014-03-03 2016-09-08 Eisai R&D Management Co., Ltd. Use of eribulin and mTOR inhibitors as combination therapy for the treatment of cancer
WO2015161285A1 (en) * 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
RU2699545C2 (ru) * 2014-05-28 2019-09-06 ЭЙСАЙ Ар ЭНД Ди МЕНЕДЖМЕНТ КО., ЛТД Применение эрибулина в лечении рака
WO2016040858A1 (en) * 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
US20160166536A1 (en) * 2014-12-12 2016-06-16 Northwestern University Combination therapy for the treatment of cancer
WO2016126889A1 (en) * 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
WO2018005533A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
EP3565558B1 (en) * 2017-01-06 2023-12-06 G1 Therapeutics, Inc. Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer
US20180371021A1 (en) * 2017-05-11 2018-12-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US20200129473A1 (en) * 2017-07-21 2020-04-30 Eisai R&D Management Co., Ltd. Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501213A (ja) * 2012-12-04 2016-01-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がんの処置におけるエリブリンの使用
WO2018016563A1 (en) * 2016-07-20 2018-01-25 Eisai R&D Management Co., Ltd. Use of eribulin and histone deacetylase inhibitors in the treatment of cancer
WO2018106729A1 (en) * 2016-12-05 2018-06-14 G1 Therapeutics, Inc. Preservation of immune response during chemotherapy regimens

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOL CAN THER, vol. 17(1_Sup.), B191, JPN6023044746, 2018, ISSN: 0005186322 *
ONCOTARGET, vol. 8(48), JPN6023044745, 2017, pages 83925 - 83939, ISSN: 0005186323 *

Also Published As

Publication number Publication date
EP3877422A4 (en) 2022-08-24
WO2020097625A1 (en) 2020-05-14
EP3877422A1 (en) 2021-09-15
CN113271977A (zh) 2021-08-17
US20210267986A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
JP2022506829A (ja) エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン
EP2739153B1 (en) Treatment of breast cancer
TWI667021B (zh) 二氫檞皮素或其醫藥上可接受之鹽、或含有彼之組合物的醫藥用途
JP7717065B2 (ja) Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
KR20160072261A (ko) 브로모도메인 및 엑스트라-말단 (bet) 단백질 저해제를 이용한 암 치료를 위한 조합 요법
CN112867512A (zh) 联合疗法
JP2013533257A (ja) 血液癌の治療法
CA3018145C (en) TREATMENT METHOD FOR TRIPLE-NEGATIVE BREAST CANCER
US20120308562A1 (en) Methods of treating mesothelioma with a pi3k inhibitor compound
JP7703124B1 (ja) Ｓｅｒｄ投薬レジメンの組み合わせを使用してがんを治療する方法
TW201922256A (zh) 治療淋巴樣惡性疾病之方法
JP2016520665A (ja) Ｍｐｓ−１キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
WO2022090443A1 (en) Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
Odhiambo et al. Preclinical evaluation of the ATR inhibitor BAY 1895344 as a radiosensitizer for head and neck squamous cell carcinoma
CN102256603B (zh) 用于在治疗中增加凋亡的有丝分裂抑制剂
JP2025535194A (ja) Ｋｒａｓ阻害剤と組み合わせたｐｉｍキナーゼ阻害剤
EP3880207B1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
WO2020254299A1 (en) Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
WO2023175477A1 (en) Treatment of breast cancer with amcenestrant
JP2023537290A (ja) 癌を処置するためのＢｃｌ－２阻害薬と低メチル化剤との組合せ、その使用及び医薬組成物
HK40059017A (en) Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations
WO2021048419A1 (en) Combination therapies comprising trametinib for the treatment of cholangiocarcinoma
EP4027996A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
US20170340629A1 (en) Masitinib combination for use in treating breast cancer
AU2022407330A1 (en) Combination therapy comprising a pkc inhibitor and a c-met inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231031

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240531